18,087 results match your criteria Rheumatoid Spondylitis


Cutaneous vasculitis in a patient with ankylosing spondylitis: A case report.

Authors:
Chao Ye Wenyuan Li

Medicine (Baltimore) 2019 Jan;98(3):e14121

Rationale: Cutaneous vasculitis is usually found in patients with rheumatoid arthritis (RA) as an extra-articular manifestation, but rare in patients with ankylosing spondylitis (AS). In this case, we describe an AS patient who developed large skin lesions, of which the histological findings were consistent with cutaneous vasculitis.

Patient Concerns: A 22-year-old male who was diagnosed as HLA-27 positive AS for 5 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014121DOI Listing
January 2019

lncRNA MEG3 is downregulated in ankylosing spondylitis and associated with disease activity, hospitalization time and disease duration.

Exp Ther Med 2019 Jan 2;17(1):291-297. Epub 2018 Nov 2.

Department of Orthopedics, Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, P.R. China.

Long non-coding (lnc)RNA maternally expressed gene 3 (MEG3) has been proved to participate in osteoporosis, which features inverse pathological changes to those associated with spondylosis. The present study aimed to investigate the involvement of lncRNA MEG3 in ankylosing spondylitis. Blood and open sacroiliac joint biopsies were obtained from ankylosing spondylitis patients and healthy controls, and the expression of MEG3 in those tissues was detected by reverse-transcription-quantitative polymerase chain reaction analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2018.6921DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307436PMC
January 2019

[Clinical Observation of Chaihu Guizhi Decoction in Treating SAPHO Syndrome].

Zhongguo Zhong Xi Yi Jie He Za Zhi 2017 04;37(4):429-432

Objective To evaluate the clinical efficacy and safety of Modified Chaihu Guizhi De- coction on SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome. Methods Totally 40 patients with SAPHO syndrome were randomized to the treatment group(20 cases) and control group(20 cases). The treatment group was treated with Modified Chaihu Guizhi Decoction, and the control group with alendronate sodium 70 mg each week. Read More

View Article

Download full-text PDF

Source

Level of adherence to prescribed exercise in spondyloarthritis and factors affecting this adherence: a systematic review.

Rheumatol Int 2019 Jan 16. Epub 2019 Jan 16.

School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, Scotland, UK.

Adherence is a primary determinant of the effectiveness of any intervention. Exercise is considered essential in the management of spondyloarthritis (SpA); however, the overall adherence to exercise programmes and factors affecting adherence are unknown. The aim of this systematic review was to examine measures of, and factors influencing adherence to, prescribed exercise programmes in people with SpA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00296-018-4225-8DOI Listing
January 2019

Efficacy of clarithromycin as a protective agent in the methotrexate-induced pulmonary fibrosis model.

Kardiochir Torakochirurgia Pol 2018 Dec 31;15(4):209-212. Epub 2018 Dec 31.

Department of Medical Oncology, School of Medicine, Mugla Sitki Kocman University, Muğla, Turkey.

Introduction: Methotrexate is a cytotoxic agent used in leukemia, and several other cancer types and at lower doses in auto-inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis and psoriasis. Macrolide antibiotics are effective against gram-positive and Gram-negative bacteria. They have anti-inflammatory activities as well. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/kitp.2018.80915DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329882PMC
December 2018

Vitamin D serum concentration is not related to the activity of spondyloarthritis - preliminary study.

Reumatologia 2018 23;56(6):388-391. Epub 2018 Dec 23.

Department of Rheumatology and Balneology, Faculty of Medicine, Jagiellonian University Medical College, Kraków, Poland.

Objective: Vitamin D plays an important role in mineral turnover and bone remodeling and there are increasing data about its immunomodulatory potential in different rheumatologic disorders. Deficiency of vitamin D is frequent in patients with spondyloarthritis (SpA) and some data suggest its association with increased disease activity and structural damage. However, its exact role in the pathogenesis of SpA and its association with disease activity are still a matter of debate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/reum.2018.80717DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330676PMC
December 2018

Evaluation of coping with chronic rheumatic disease, in the context of socio-demographic factors and disease duration, based on the example of patients with ankylosing spondylitis.

Reumatologia 2018 23;56(6):368-376. Epub 2018 Dec 23.

Department of Integrated Medical Care, Medical University of Białystok, Poland.

Objectives: Ankylosing spondylitis (AS) impairs patients' functioning, reducing their quality of life. The author of salutogenesis, Antonovsky, claims that maintaining an inner balance in a chronic disease is possible through a high sense of coherence. The aim of the current study was to identify socio-demographic factors and disease duration related to the feeling of coherence of patients with AS, acceptance of disease and risk of depression. Read More

View Article

Download full-text PDF

Source
https://www.termedia.pl/doi/10.5114/reum.2018.80714
Publisher Site
http://dx.doi.org/10.5114/reum.2018.80714DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330684PMC
December 2018
1 Read

Opioid Use in Patients with Ankylosing Spondylitis is Common in the United States: Outcomes of a Retrospective Cohort Study.

J Rheumatol 2019 Jan 15. Epub 2019 Jan 15.

From UCB Pharma, Raleigh, NC, USA; Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA; UCB Pharma, Smyrna, GA, USA. UCB sponsored the study and the development of the manuscript and reviewed the text to ensure that from UCB perspective, the data presented in the publication are scientifically, technically and medically supportable, that they do not contain any information that has the potential to damage the intellectual property of UCB, and that the publication complies with applicable laws, regulations, guidelines and good industry practice. The authors approved the final version to be published after critically revising the manuscript for important intellectual content. All listed authors are employees of UCB Pharma. In addition, VSS is a holder of stock and options in UCB Pharma, and AS, JLS and RYS are shareholders in UCB Pharma. Address correspondence to Victor S. Sloan, UCB Pharma, 8010 Arco Corporate Dr, Raleigh, NC 27617, USA. Phone: +1 919-767-1650. Email:

Objective: To assess the prevalence of chronic opioid use in patients with ankylosing spondylitis (AS), and compare the characteristics of patients with and without chronic opioid use.

Methods: This was a retrospective cohort study of AS patients identified in the Truven MarketScan® database between 01-Jan-2012 and 31-Mar-2017. Commercial and Medicaid claims data were examined using both specific (720. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3899/jrheum.180972DOI Listing
January 2019

Association between IL23R and ERAP1 polymorphisms and sacroiliac or spinal MRI inflammation in spondyloarthritis: DESIR cohort data.

Arthritis Res Ther 2019 Jan 15;21(1):22. Epub 2019 Jan 15.

Centre de rhumatologie, CHU de Toulouse, UMR 1043, CPTP, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France.

Background: To investigate the association between 12 single nucleotide polymorphisms (SNPs) located on ERAP1 and IL23R with the presence of inflammation on the sacroiliac joint (SIJ) or spinal magnetic resonance imagery (MRI) in an early onset spondyloarthritis (SpA) cohort.

Methods: All the patients included in the DESIR cohort with an axial SpA and available DNA at baseline were enrolled in this study (n = 645 patients) and underwent a clinical examination, CRP assay, SIJ and spinal MRI scans. Six SNPs located on ERAP1 (rs30187, rs27044, rs27434, rs17482078, rs10050860, rs2287987) and six SNPs located on IL23R (rs1004819, rs10489629, rs1343151, rs2201841, rs10889677, rs11209032) were genotyped. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-018-1807-5DOI Listing
January 2019
1 Read

YouTube as a source of patient information for ankylosing spondylitis exercises.

Clin Rheumatol 2019 Jan 15. Epub 2019 Jan 15.

Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Kahramanmaraş Sütçü İmam University, Kahramanmaraş, Turkey.

Introduction/objectives: Ankylosing spondylitis (AS) is a rheumatic disorder characterized by structural impairments and postural deformities which restrict daily life activities. Nonpharmacologic methods, particularly exercise therapies, play a key role in the treatment. Obtaining online health-related information has become increasingly popular. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-018-04413-0DOI Listing
January 2019

Coexistence of systemic sclerosis and ankylosing spondylitis: A case report and literature review.

Zhong Nan Da Xue Xue Bao Yi Xue Ban 2018 Nov;43(11):1263-1265

Department of Rheumatology and Immunology, Xiangya Hospital, Central South University; Institute of Rheumatology and Immunology, Central South University, Changsha 410008, China.

Systemic sclerosis (SSc) is an autoimmune disease characterized by thickening of the skin and organ fibrosis. Ankylosing spondylitis (AS) is a type of arthritis with long-term inflammation of the axial joints. Previous studies presented 5 cases of concomitant AS and SSc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11817/j.issn.1672-7347.2018.11.016DOI Listing
November 2018

TNF-α Inhibitors Decrease Classical CD14CD16- Monocyte Subsets in Highly Active, Conventional Treatment Refractory Rheumatoid Arthritis and Ankylosing Spondylitis.

Int J Mol Sci 2019 Jan 12;20(2). Epub 2019 Jan 12.

Department of Internal and Agricultural Medicine, Faculty of Medicine, Jagiellonian University Medical College, 31-121 Krakow, Poland.

Monocytes are pivotal cells in inflammatory joint diseases. We aimed to determine the effect of TNF-α inhibitors (TNFi) on peripheral blood monocyte subpopulations and their activation in ankylosing spondylitis (AS) and rheumatoid arthritis (RA) patients with high disease activity. To address this, we studied 50 (32 AS, 18 RA) patients with highly active disease with no prior history of TNFi use who were recruited and assigned to TNFi or placebo treatment for 12 weeks. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/1422-0067/20/2/291
Publisher Site
http://dx.doi.org/10.3390/ijms20020291DOI Listing
January 2019
1 Read

[The prevalence of latent tuberculosis infection in patients with inflammatory arthritis and the diagnostic efficacy of different screening methods].

Zhonghua Yi Xue Za Zhi 2019 Jan;99(1):20-24

Department of Rheumatology and Immunology, Peking University International Hospital, Beijing 102206, China.

To investigate the prevalence of latent tuberculosis infection (LTBI) in patients with inflammatory arthritis, and to compare the efficacy of tuberculin skin test (TST) and QuantiFERON-TB Gold (QFT) in screening for LTBI in these patients. Medical records of 149 patients with inflammatory arthritis admitted to inpatient of Peking University International Hospital from December 2015 to December 2017 (diagnosis with rheumatoid arthritis, ankylosing spondylitis, sero-negative spondyloarthropathy, psoriatic arthritis, or reactive arthritis) who accepted TST or QFT were collected. The information included gender, age, history of tuberculosis infection, calcifications presence in chest X-ray or chest CT, TST result, QFT result, medication history before test, and biological treatment and all the patients were made a follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0376-2491.2019.01.005DOI Listing
January 2019
1 Read

[Effect of Xinfeng Capsule on Related Factors of Thrombus Formation and Inflammatory Cytokines in Active Ankylosing Spondylitis Patients].

Zhongguo Zhong Xi Yi Jie He Za Zhi 2016 10;36(10):1202-1207

Objective To observe the effect of Xinfeng Capsule (XFC) on related factors of thrombus formation and inflammatory cytokines in active ankylosing spondylitis (AS) patients. Methods Seventy-six active AS patients were assigned to the XFC group and the Sulfasalazine treated group (SASP group) , 38 in each group according to random digits table. Patients in the SASP group took SASP, 0. Read More

View Article

Download full-text PDF

Source
October 2016

Increased Risk of Heterotopic Ossification Following Revision Hip Arthroplasty for Periprosthetic Joint Infection.

Arch Bone Jt Surg 2018 Nov;6(6):486-491

Research performed at The Rothman Institute at Thomas Jefferson University, Philadelphia, PA, USA.

Background: To investigate whether surgery for Periprosthetic Joint Infection (PJI) of the hip, the number of procedures and their duration contribute to risk of Heterotopic Ossification formation.

Methods: 56 patients with hip PJI undergoing one-stage (10) or two-stage (46) exchange arthroplasty were matched to 112 patients undergoing revision arthroplasty for aseptic failure based on age, gender, body mass index (BMI), surgical approach (all direct lateral) and date of surgery (2006-2013). Patients with Paget's disease and ankylosing spondylitis, or preoperative HO were excluded. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310194PMC
November 2018
1 Read

[Effects of serial mud baths on inflammatory rheumatic and degenerative diseases].

Z Rheumatol 2019 Jan 9. Epub 2019 Jan 9.

Abteilung Rheumatologie, Klinische Immunologie, Physikalische Medizin und Osteologie, Kerkhoff-Klinik, Justus-Liebig-Universität Gießen, Bad Nauheim, Deutschland.

Background: Mud baths have been used for a long time for the treatment of musculoskeletal diseases. In addition to a reduction of pain and improved function, serially applied mud baths lead to a reduction in the inflammatory processes, which often underlie degenerative and inflammatory rheumatic diseases.

Objective: This study investigated the effects of serial mud baths on parameters of functional health, on pain perception and at the molecular level in patients with inflammatory rheumatic diseases, e. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00393-018-0582-7
Publisher Site
http://dx.doi.org/10.1007/s00393-018-0582-7DOI Listing
January 2019
2 Reads

Clinical and Genetic Aspects of Behçet's Disease in Japan.

Intern Med 2019 Jan 10. Epub 2019 Jan 10.

Department of Stem Cell and Immune Regulation, Yokohama City University, Graduate School of Medicine, Japan.

Patients with Behçet's disease (BD) suffer from episodic ocular and mucocutaneous attacks, resulting in a reduced quality of life. The phenotype of Japanese BD has been changing over the past 20 years, and the rate of HLA-B*51-positive complete type is decreasing while that of intestinal type is increasing. This phenotypical evolution may be related to changes in as-yet-unknown environmental factors, as the immigration influx in Japan is low. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.2035-18DOI Listing
January 2019
1 Read

High prevalence of hip involvement and decrease in inflammatory ultrasound lesions during tumour necrosis factor-α blocking therapy in ankylosing spondylitis.

Rheumatology (Oxford) 2019 Jan 8. Epub 2019 Jan 8.

Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Objectives: To assess the prevalence of clinical, US and radiographic hip involvement in AS patients with active disease and to explore the associations between these assessments. Furthermore, to evaluate the effect of 6 months of TNF-α blocking therapy on tender and inflammatory power Doppler US lesions of hip joints.

Methods: Consecutive AS patients starting TNF-α blocking therapy were evaluated for hip joint involvement. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/rheumatology/advance-article/doi/10
Publisher Site
http://dx.doi.org/10.1093/rheumatology/key382DOI Listing
January 2019
1 Read

Measuring outcomes in ankylosing spondylitis: pearls and pitfalls.

Curr Opin Rheumatol 2019 Jan 7. Epub 2019 Jan 7.

Allergy, Immunology Division, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, USA.

Purpose Of Review: Patients with ankylosing spondylitis (AS) warrant a comprehensive clinical assessment because of the lack of biomarkers of disease activity, prognosis and response to biologic therapy. Multiple AS-related questionnaires have been developed to assess the disease status accurately, but feasibility remains a problem in clinical practice. The purpose of this review is to assess the pearls and pitfalls of AS-related outcome measures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000588DOI Listing
January 2019
1 Read

Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis.

Arthritis Res Ther 2019 Jan 8;21(1):11. Epub 2019 Jan 8.

Rheumatology Department, Hospital Clínic de Barcelona - Universitat de Barcelona, Barcelona, Spain.

Objective: The objective was to determine if dose reduction is non-inferior to full-dose TNFi to maintain low disease activity (LDA) in patients already in remission with TNFi, in axial spondyloarthritis.

Methods: Randomized, parallel, non-inferiority, open-label multicentre clinical trial. Patients were eligible if they had axial spondyloarthritis and had been in clinical remission for ≥ 6 months with any available TNFi (adalimumab, etanercept, infliximab, golimumab) at the dose recommended by product labelling. Read More

View Article

Download full-text PDF

Source
https://arthritis-research.biomedcentral.com/articles/10.118
Publisher Site
http://dx.doi.org/10.1186/s13075-018-1772-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323809PMC
January 2019
3 Reads

Incidence of first cardiovascular event in Spanish patients with inflammatory rheumatic diseases: prospective data from the CARMA project.

Clin Exp Rheumatol 2019 Jan 3. Epub 2019 Jan 3.

Div. Rheumatology, Univ. Cantabria, Hosp. Univ. Marqués de Valdecilla, Santander; Epidemiology, Genetics and Atherosclerosis Res. Group on Systemic Inflammatory Diseases, Rheumatology Div., IDIVAL, Santander, Spain; Univ.of the Witwatersrand, South Africa.

Objectives: To determine the incidence and risk factors of first cardiovascular event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD).

Methods: Analysis of data after 2.5 years of follow-up from the prospective study CARMA project, that includes patients with CIRD [rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA)] and matched individuals without CIRD from 67 hospitals in Spain. Read More

View Article

Download full-text PDF

Source
January 2019
2 Reads

Targeting Inflammation to Prevent Cardiovascular Disease in Chronic Rheumatic Diseases: Myth or Reality?

Front Cardiovasc Med 2018 11;5:177. Epub 2018 Dec 11.

Rheumatology Unit, Department of Perugia, University of Perugia, Perugia, Italy.

Evidence for increased risk of cardiovascular morbidity and mortality in chronic inflammatory rheumatic diseases has accumulated during the last years. Traditional cardiovascular risk factors contribute in part to the excess of cardiovascular risk in these patients and several mechanisms, including precocious acceleration of subclinical atherosclerotic damage, inflammation, and immune system deregulation factors, have been demonstrated to strictly interplay in the induction and progression of atherosclerosis. In this setting, chronic inflammation is a cornerstone of rheumatic disease pathogenesis and exerts also a pivotal role in all stages of atherosclerotic damage. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fcvm.2018.00177/
Publisher Site
http://dx.doi.org/10.3389/fcvm.2018.00177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297850PMC
December 2018
1 Read

Genetics and Functional Genomics of Spondyloarthritis.

Front Immunol 2018 18;9:2933. Epub 2018 Dec 18.

UMR 1173 INSERM/Versailles Saint-Quentin-en-Yvelines University, Montigny le Bretonneux, France.

Spondyloarthritis (SpA) is a chronic inflammatory disorder with high heritability but with complex genetics. It encompasses several entities that share common clinical features. Most of the genetic studies in SpA have been restricted to ankylosing spondylitis (AS), the prototypical form of SpA. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2018.02933
Publisher Site
http://dx.doi.org/10.3389/fimmu.2018.02933DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305624PMC
December 2018
1 Read

Thinking Positive in Spondyloarthritis.

Authors:
Nigil Haroon

Arthritis Rheumatol 2019 Jan 7. Epub 2019 Jan 7.

Spondylitis Program, University Health Network, University of Toronto, Toronto, ON.

What is so negative about seronegative diseases? The term seronegative arthritis can be confusing. Does this refer to seronegative rheumatoid arthritis (RA) or spondyloarthritis (SpA)? We diagnose patients with seronegative RA if the clinical picture is consistent with RA and yet they lack serum markers such as rheumatoid factor and anti-cyclic citrullinated peptide antibodies. However, for SpA the absence of RF is a common cardinal feature, despite the varied presentations. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/art.40832
Publisher Site
http://dx.doi.org/10.1002/art.40832DOI Listing
January 2019
1 Read

Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review.

Drugs Real World Outcomes 2019 Jan 7. Epub 2019 Jan 7.

University of Texas Medical Branch, Galveston, TX, USA.

Objectives: To characterize US patients with ankylosing spondylitis (AS) who were treated with secukinumab and to assess rheumatologist-reported reasons for prescribing treatment in clinical practice.

Methods: This descriptive analysis of data from a US retrospective medical chart review included patients aged ≥ 18 years diagnosed with AS who initiated secukinumab after 15 January 2016. Eligible rheumatologists used online forms to collect patient demographics, disease characteristics, co-morbidity profile, and treatment history prior to or on the index date, defined as the date of the first secukinumab prescription recorded in the medical chart. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40801-018-0146-9DOI Listing
January 2019

The relationship between global spinal alignment and pelvic orientation from standing to sitting following pedicle subtraction osteotomy in ankylosing spondylitis patients with thoracolumbar kyphosis.

Arch Orthop Trauma Surg 2019 Jan 4. Epub 2019 Jan 4.

Spine Surgery, Drum Tower Hospital of Nanjing University Medical School, Zhongshan Road 321, Nanjing, 210008, China.

Introduction: To investigate the relationship between the spinal sagittal alignment and arc of pelvic motion from standing to sitting in ankylosing spondylitis (AS) patients with thoracolumbar kyphosis following pedicle subtraction osteotomy (PSO).

Materials And Methods: AS patients who underwent PSO for thoracolumbar kyphosis from January 2016 to July 2018 were recruited. EOS standing and sitting images were obtained pre- and postoperatively. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00402-018-03107-1
Publisher Site
http://dx.doi.org/10.1007/s00402-018-03107-1DOI Listing
January 2019
1 Read

The gait deviations of ankylosing spondylitis with hip involvement.

Clin Rheumatol 2019 Jan 4. Epub 2019 Jan 4.

Department of Orthopedics, Changhai Hospital Affiliated to the Second Military Medical University, No. 168 Changhai Road, Shanghai, China.

Objective: The aim of the study was to investigate the gait deviations of ankylosing spondylitis (AS) patients with hip involvement.

Methods: Thirty-six subjects, including 18 AS patients with hip involvement (AS group) and 18 healthy people (control subjects, CS group), were enrolled in the study. Three-dimensional gait analysis of the AS group and CS group was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-018-4401-yDOI Listing
January 2019

[Value of Diffusion-weighted Imaging in Evaluating the Activity of Sacroiliitis in Ankylosing Spondylitis].

Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2018 Dec;40(6):723-729

Department of Radiology,Peking University Third Hospital,Beijing 100191,China.

Objective To investigate the clinical value of diffusion-weighted imaging (DWI) for evaluating the activity of sacroiliitis in ankylosing spondylitis (AS).Methods Totally 73 AS patients were prospectively enrolled and divided into active group (n=43) and chronic group (n=30) according to Bath ankylosing spondylitis disease activity index (BASDAI) scores and laboratory findings. Conventional magnetic resonance imaging (MRI) and DWI were performed in all subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3881/j.issn.1000-503X.10602DOI Listing
December 2018

Neutrophil lymphocyte ratio in Patients with Ankylosing Spondylitis: A Systematic Review and Meta-Analysis.

Mod Rheumatol 2019 Jan 3:1-19. Epub 2019 Jan 3.

a Department of Epidemiology and Biostatistics , School of Public Health, Anhui Medical University , Hefei , Anhui , China.

Objective: The aim of this meta-analysis was to investigate the association of neutrophil lymphocyte ratio (NLR) with AS (ankylosing spondylitis) patients.

Methods: PubMed, Web of Science, Cochrane Library, Elsevier Science Direct and Google Scholar databases (up to 30 Sep, 2018) were searched to collect all pertinent articles. The pooled standard mean difference(SMD) with 95% confidence interval (CI) was calculated by the random effects model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14397595.2018.1564165DOI Listing
January 2019

A Curious Case of Ankylosing Spondylosis and Motor Neuron Disease: A Mere Coincidence or Correlation?

Int J Appl Basic Med Res 2018 Oct-Dec;8(4):266-268

Department of Medicine, B. R. Singh Hospital, Kolkata, West Bengal, India.

Ankylosing spondylitis (AS) is a chronic (progressive) painful inflammatory rheumatic disease with genetic predisposition. Genetic susceptibility and common expression cause susceptibility to other inflammatory diseases such as psoriasis, ulcerative colitis, and Crohn's disease. However, cases of motor neuron disease (MND) in patients of biologically treated patients of AS have been rarely reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijabmr.IJABMR_72_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6259304PMC
January 2019
1 Read

Identification of the key genes and long non‑coding RNAs in ankylosing spondylitis using RNA sequencing.

Int J Mol Med 2018 Dec 20. Epub 2018 Dec 20.

Department of Orthopedics, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, P.R. China.

Ankylosing spondylitis (AS) is an insidious and debilitating form of arthritis that involves the axial skeleton, and its etiology and pathogenesis remain unclear. In the present study, three patients with AS and three normal controls from our hospital were enrolled. RNA sequencing and bioinformatics analysis were performed in order to identify the differentially expressed (DE) mRNAs (DEmRNAs) and DE long non‑coding RNAs (DElncRNAs) between the patients with AS and normal controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijmm.2018.4038DOI Listing
December 2018

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.

Rheumatology (Oxford) 2018 Dec 19. Epub 2018 Dec 19.

Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Objectives: To evaluate the effect of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, on efficacy, imaging outcomes, and safety through 4 years (208 weeks) in patients with ankylosing spondylitis.

Methods: Patients opting to enrol had completed 2 years' treatment in the MEASURE 1 core study with subcutaneous secukinumab 150 or 75 mg every 4 weeks (q4Wk), following intravenous loading to Week (Wk) 4, or placebo treatment to Wk16/24. Up-titration from secukinumab 75-150 mg q4Wk was permitted following a protocol amendment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/key375DOI Listing
December 2018

Axial spondyloarthritis in the USA: diagnostic challenges and missed opportunities.

Clin Rheumatol 2018 Dec 26. Epub 2018 Dec 26.

Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA.

Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease that primarily affects the sacroiliac joints and spine. Delayed or inadequate treatment may decrease quality of life and lead to poor long-term outcomes, including irreversible loss of spinal function. In this review, we discuss clinical practice related to axSpA within the USA, including prevalence, diagnosis, reasons for delayed/missed diagnosis, and suggestions for making early diagnosis. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10067-018-4397-3
Publisher Site
http://dx.doi.org/10.1007/s10067-018-4397-3DOI Listing
December 2018
5 Reads
1.774 Impact Factor

Factors related to health-related quality of life in ankylosing spondylitis, overall and stratified by sex.

Arthritis Res Ther 2018 Dec 27;20(1):284. Epub 2018 Dec 27.

Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, 901 87, Umeå, Sweden.

Background: Ankylosing spondylitis (AS) begins early in life and often leads to reduced physical function, but less is known about the impacts it has on health-related quality of life (HRQoL). The aims of this study were to assess HRQoL using the Short Form-36 (SF-36) in a cohort of patients with AS compared with controls and to examine associations between SF-36 scores and spinal radiographic changes, physical function, disease activity and demographic data overall and stratified by sex.

Methods: A cohort of patients with AS from Western Sweden were assessed using the Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) with spinal radiographs, clinical examination and questionnaires, including the Bath Ankylosing Spondylitis Metrology Index, Bath Ankylosing Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP), Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Patient Global (BASG) and SF-36. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13075-018-1784-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307231PMC
December 2018
1 Read

Clinical assessment and ultrasonography in the follow-up of enthesitis in patients with spondyloarthritis: a multicenter ultrasound study in daily clinical practice.

Open Access Rheumatol 2018 3;10:161-169. Epub 2018 Dec 3.

AbbVie, 65189 Wiesbaden, Germany.

Objectives: The aim of this study was to compare the clinical Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) and an established ultrasound enthesitis score following treatment change in patients with spondyloarthritis and enthesitis with respect to the sensitivity to change and health-related quality of life.

Materials And Methods: About 145 patients with active ankylosing spondylitis (n=65), psoriatic arthritis without (n=66) or with (n=14) axial involvement undergoing intensification of their treatment were included in this multicenter study. At baseline, after 3 and 6 months, 13 entheses were scored by MASES, ultrasonography was performed for 14 entheses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OARRR.S179472DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284849PMC
December 2018
1 Read

[Total hip arthroplasty for the treatment of bony ankylosis in patients with ankylosing spondylitis].

Zhongguo Gu Shang 2018 Dec;31(12):1104-1107

Department of Orthopaedics, Zhoushan Hospital of Traditional Chiniese Medicine Affiliated to Zhejiang Chinese Medical University, Zhoushan 316000, Zhejiang, China.

Objective: To evaluate the efficacy of total hip arthroplasty for the treatment of bony ankylosis in patients with ankylosing spondylitis.

Methods: From January 2008 to January 2012, 12 patients (24 hips) with ankylosing spondylitis combined with hip ankylosis were treated with total hip arthroplasty, including 11 males and 1 females, ranging in age from 27 to 62 years old. The course of diseases ranged from 5 to 32 years old. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3969/j.issn.1003-0034.2018.12.006DOI Listing
December 2018
1 Read

Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy.

Clin Exp Rheumatol 2018 Nov-Dec;36 Suppl 115(6):68-73. Epub 2018 Dec 12.

Research Centre of Systemic Autoinflammatory Diseases and Behçet's Disease and Rheumatology-Ophthalmology Collaborative Uveitis Centre, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.

Objectives: To describe the epidemiology of non-infectious uveitis (NIU) in two tertiary referral rheumatology units in Central and Southern Italy.

Methods: Two hundred and seventy-eight consecutive NIU patients (417 eyes) evaluated between January 2016 and January 2017 were enrolled. Collected data were analysed in accordance with the primary anatomic site of inflammation, clinical course, and laterality. Read More

View Article

Download full-text PDF

Source
December 2018
2 Reads

Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data.

J Adv Res 2019 Jan 19;15:87-93. Epub 2018 Sep 19.

Institute of Epidemiology, Academic Hospital Santa Maria della Misericordia, Udine, Italy.

Risk of hospitalized infections under biologics among patients suffering from chronic inflammatory autoimmune diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PSA), or psoriasis was investigated using administrative data. The hospital discharge records database, the medical prescription database, and the database of exemptions from medical charges were linked at the individual patient level. A cohort of patients diagnosed with RA, SA, PSA, and severe psoriasis from 2006 to 2017 was identified and followed-up to either the end of 2017 or hospitalization with the main discharge diagnosis of infection, death, or they moved out of the region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jare.2018.09.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300460PMC
January 2019
2 Reads

The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.

Expert Rev Clin Immunol 2019 Feb 8;15(2):123-134. Epub 2019 Jan 8.

a NIHR Leeds Biomedical Research Centre , Leeds Teaching Hospitals NHS Trust , Leeds , UK.

Introduction: Secukinumab, an interleukin-17A (IL-17A) antagonist, is the first non-TNF alpha inhibitor agent licensed for ankylosing spondylitis (AS), which opens up a new era of alternative cytokine targets beyond TNF. Areas covered: This review explores the pathophysiology and scientific evidence behind the use of this new mode of action and discusses the basis for its efficacy and clinical utility in the management of AS. In particular, how the emergent data points towards the efficacy of secukinumab and ixekizumab, a second emergent IL-17A blocker, in AS has helped focus research into the IL-23/17 axis in entheseal driven disease in man and how IL-17A inhibition may be linked to the presence of innate and adaptive immune cell populations capable of IL-17A elaboration in these target tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1561281DOI Listing
February 2019
1 Read

[Nonsurgical and surgical management of osteoporotic vertebral body fractures : Recommendations of the Spine Section of the German Society for Orthopaedics and Trauma (DGOU)].

Orthopade 2018 Dec 20. Epub 2018 Dec 20.

Zentrum für Hand- und Wirbelsäulenchirurgie, Klinikum Traunstein, Traunstein, Deutschland.

Study Design: Prospective clinical cohort study (data collection); expert opinion (recommendation development).

Objectives: Treatment options for nonsurgical and surgical management of osteoporotic vertebral body fractures differ widely. Based on the current literature, the knowledge of the experts, and their classification for osteoporotic fractures (OF classification), the Spine Section of the German Society for Orthopaedics and Trauma has now introduced general treatment recommendations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00132-018-03666-6DOI Listing
December 2018

Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD).

Open Access Rheumatol 2018 27;10:151-160. Epub 2018 Nov 27.

Janssen-Cilag Pty Ltd, Sydney, NSW, Australia,

Introduction: To describe the persistence of treatment with subcutaneous tumor necrosis factor inhibitors (TNFi) adalimumab, etanercept, and golimumab in immune-mediated rheumatic disease (rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis) by treatment sequence (first-line treatment, second-line or further lines of treatment).

Methods: A retrospective cohort analysis was conducted using the Australian Commonwealth Department of Human Services Pharmaceutical Benefits Scheme 10% sample data from January 1, 2010, to June 30, 2016. Pharmaceutical Benefits Scheme indications were used to identify patient prescriptions for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OARRR.S179704DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267492PMC
November 2018
1 Read

Assessment of the validity and reliability of the Jenkins Sleep Scale in ankylosing spondylitis.

Int J Rheum Dis 2018 Nov 22. Epub 2018 Nov 22.

PMR Department, School of Medicine, Marmara University, Istanbul, Turkey.

Aim: Ankylosing spondylitis (AS) affects sleep quality. Jenkins Sleep Scale (JSS) Evaluation Questionnaire is a simple and easy to understand scale. The aim of this study is to constitute validity and reliability of JSS-TR in AS patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1756-185X.13447DOI Listing
November 2018

It is time for an organised, scientific approach to the application of patient-reported outcome measures in clinical studies and trials.

Clin Rheumatol 2018 Dec 18. Epub 2018 Dec 18.

Galen Research, Manchester, UK.

Too often, clinicians and researchers assume that patient-reported outcome measures (PROMs) are simply designed, can be changed to suit specific circumstances and should be freely available for use without seeking permission. If a version is not easily available, they believe they can produce a new translation without relevant experience or expertise. Copyright issues are inconvenient and commonly ignored, despite some journals requesting confirmation from authors that permission had been granted for use of copyrighted materials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-018-04403-2DOI Listing
December 2018

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study.

RMD Open 2018 27;4(2):e000766. Epub 2018 Nov 27.

Division of Rheumatology, Department of Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.

Objective: To investigate the occurrence of ankylosing spondylitis (AS)-related sick leave (SL) over 6 12 years and explore factors predicting first and recurrent SL.

Methods: Data from employed patients from the Outcome in Ankylosing Spondylitis International Study were used. At each visit, patients indicated the occurrence of SL (yes/no) in the previous inter-assessment period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2018-000766DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269643PMC
November 2018

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies.

RMD Open 2018 21;4(2):e000749. Epub 2018 Nov 21.

Leiden University Medical Centre, Leiden, The Netherlands.

Objective: To evaluate the magnitude of response to secukinumab treatment over 3 years in patients with ankylosing spondylitis (AS) grouped by baseline C-reactive protein (CRP) levels in a pooled study of two pivotal phase III studies: MEASURE 1 (NCT01358175) and MEASURE 2 (NCT01649375).

Methods: This post hoc analysis pooled data from all patients with available baseline CRP in the two studies who received subcutaneous secukinumab 150  mg (approved dose; N=197) or placebo (N=195). Assessed efficacy endpoints included Assessments of SpondyloArthritis international Society (ASAS)20/40, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), BASDAI50, AS Disease Activity Score inactive disease and ASAS partial remission among patients grouped by baseline CRP based on central laboratory cut-off <5  mg/L (normal) or ≥5  mg/L (elevated) and a cut-off <10  mg/L or ≥10  mg/L. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/rmdopen-2018-000749DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269637PMC
November 2018

[Progressive pseudorheumatoid dysplasia misdiagnosed as ankylosing spondylitis: a case report].

Beijing Da Xue Xue Bao Yi Xue Ban 2018 Dec;50(6):1112-1116

Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing 100191, China.

In this study, we reported a case of progressive pseudorheumatoid dysplasia in Peking University Third Hospital. A 56-year-old male patient presented with hip joint pain for more than 40 years and multiple joints pain with limitation of movements of these joints for 28 years. This patient suffered from joint pain and impaired range of motion of the hip, knee, elbow and shoulder gradually, associated with difficulty in walking and inability to take care of himself. Read More

View Article

Download full-text PDF

Source
December 2018
6 Reads

Associations between smoking and extra-axial manifestations and disease severity in axial spondyloarthritis: results from the BSR Biologics Register for Ankylosing Spondylitis (BSRBR-AS).

Rheumatology (Oxford) 2018 Dec 14. Epub 2018 Dec 14.

Musculoskeletal biology I, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.

Objective: The effects of smoking on disease manifestations in axial SpA are inadequately described. Utilizing a large and well-characterized cohort, we investigated the association between smoking and extra-axial manifestations, and smoking and disease severity measures.

Methods: Baseline data from the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis were explored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/key371DOI Listing
December 2018

Associated factors with adherence to standard exercise therapy and health-related quality of life in Chinese patients with ankylosing spondylitis.

Mod Rheumatol 2018 Dec 18:1-16. Epub 2018 Dec 18.

b Research Center of Clinical Medicine , Affiliated Hospital of Nantong University , 20th Xisi Road , 226001 , Nantong , China .

Objectives: The aim of this study is to assess the current situations of standard exercise treatment and predictors of non-standard exercise in Chinese patients with ankylosing spondylitis (AS). An analysis of the effect of standard exercise on health-related quality of life (HR-QoL) was also conducted.

Methods: In the cross-sectional study, a total of 259 AS patients were constantly invited to participate in this study and complete the questionnaire under the researchers' supervision in a clinical setting including sociodemographic variables, clinical variables, psychological variables and HR-QoL. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14397595.2018.1
Publisher Site
http://dx.doi.org/10.1080/14397595.2018.1559966DOI Listing
December 2018
2 Reads
2.206 Impact Factor

Anti-SIRT1 autoantibody is elevated in ankylosing spondylitis: a potential disease biomarker.

BMC Immunol 2018 Dec 17;19(1):38. Epub 2018 Dec 17.

Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin Second Road, Shanghai, 200025, China.

Background: Little is known about the presence of specific autoantibodies in ankylosing spondylitis (AS), an immune-mediated inflammatory disease. The object of this study was to explore potential autoantibody profiles in AS patients.

Results: Levels of anti-SIRT1 autoantibodies were significantly higher in AS (P < 0. Read More

View Article

Download full-text PDF

Source
https://bmcimmunol.biomedcentral.com/articles/10.1186/s12865
Publisher Site
http://dx.doi.org/10.1186/s12865-018-0280-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298004PMC
December 2018
4 Reads
2.481 Impact Factor